Article Text

Download PDFPDF

005.1 Real-time pcr and melt curve analysis targeting gyra gene for prediction of ciprofloxacin resistance in clinical neisseria gonorrhoeae isolates
  1. P Hemarajata1,
  2. S Yang1,
  3. OO Soge2,
  4. RM Humphries1,
  5. JD Klausner3
  1. 1Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, USA
  2. 2Neisseria Reference Laboratory, GISP Regional Laboratory, University of Washington Harborview Medical Center, USA
  3. 3Division of Infectious Diseases, Center for World Health and Department of Epidemiology, David Geffen School of Medicine and Fielding School of Public Health, UCLA, USA


Introduction Increasing antimicrobial resistance in Neisseria gonorrhoeae has been a major problem worldwide, limiting effective empirical therapeutic options in patients infected with multi-drug resistant strains. Guidelines from U.S. CDC no longer recommend treatment with fluoroquinolones (FQs) due to emergence of resistance nationally. However, current prevalence of resistance in the US is still low at 12% and treatment with FQs may be a viable option for susceptible isolates. A rapid molecular test predicting FQ susceptibility in N. gonorrhoeae isolates would help physicians in determining an effective treatment plan for each patient.

Methods Twenty-three ciprofloxacin (CIP)-susceptible and 77 CIP-resistant clinical N. gonorrhoeae isolates were obtained from Neisseria Reference Laboratory at University of Washington and grown on chocolate agar plates. To determine the association between mutations in gyrA gene and CIP resistance in those isolates, we extracted DNA from culture and performed real-time PCR on a Lightcycler 480 based on the HybProbe system targeting gyrA gene followed by melt curve genotyping.

Results Melt curve genotyping analysis demonstrated wild-type melt patterns in all (100%) 23 CIP-susceptible isolates, while all 77 (100%) CIP-resistant isolates demonstrated mutant melt patterns.

Conclusion There was a 100% concordance between PCR melt genotypes and CIP susceptibility among all clinical isolates tested. The assay is currently being validated for testing on DNA extracted directly from clinical specimens ultimately to be offered for use in clinical practice.

Disclosure of interest statement This study was funded in part by NIH R21AI109005.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.